Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas

References

1. 1.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
2. 2.↵
   2. Eckel-Passow JE,
   3. Lachance DH,
   4. Molinaro AM, et al

   . Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–508 doi:10.1056/NEJMoa1407279 pmid:26061753

   CrossRefPubMed
3. 3.↵
   2. Brat DJ,
   3. Verhaak RG,
   4. Aldape KD, et al

   ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
4. 4.↵
   2. Louis DN,
   3. Perry A,
   4. Burger P, et al

   . International Society of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24:429–35 doi:10.1111/bpa.12171 pmid:24990071

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Kaloshi G,
   3. Benouaich-Amiel A,
   4. Diakite F, et al

   . Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831–36 doi:10.1212/01.wnl.0000262034.26310.a2 pmid:17515545

   CrossRefPubMed
6. 6.↵
   2. Gutman DA,
   3. Cooper LA,
   4. Hwang SN, et al

   . MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013;267:560–69 doi:10.1148/radiol.13120118 pmid:23392431

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Mazurowski MA,
   3. Desjardins A,
   4. Malof JM

   . Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro Oncol 2013;15:1389–94 doi:10.1093/neuonc/nos335 pmid:23396489

   CrossRefPubMed
8. 8.↵
   2. Gutman DA,
   3. Dunn WD Jr.,
   4. Grossmann P, et al

   . Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology 2015;57:1227–37 doi:10.1007/s00234-015-1576-7 pmid:26337765

   CrossRefPubMed
9. 9.↵
   2. Yan H,
   3. Parsons DW,
   4. Jin G, et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Takano S,
    3. Tian W,
    4. Matsuda M, et al

    . Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011;28:115–23 doi:10.1007/s10014-011-0023-7 pmid:21344322

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Riemenschneider MJ,
    3. Jeuken JW,
    4. Wesseling P, et al

    . Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010;120:567–84 doi:10.1007/s00401-010-0736-4 pmid:20714900

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Beiko J,
    3. Suki D,
    4. Hess KR, et al

    . IDH1-mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014;16:81–91 doi:10.1093/neuonc/not159 pmid:24305719

    CrossRefPubMed
13. 13.↵
    2. Wang S,
    3. Kim S,
    4. Chawla S, et al

    . Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 2009;44:653–60 doi:10.1016/j.neuroimage.2008.09.027 pmid:18951985

    CrossRefPubMedWeb of Science
14. 14.↵
    2. van den Bent MJ,
    3. Brandes AA,
    4. Taphoorn MJ, et al

    . Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–50 doi:10.1200/JCO.2012.43.2229 pmid:23071237

    Abstract/FREE Full Text
15. 15.↵
    2. Cairncross G,
    3. Wang M,
    4. Shaw E, et al

    . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 doi:10.1200/JCO.2012.43.2674 pmid:23071247

    Abstract/FREE Full Text
16. 16.↵
    2. Rohle D,
    3. Popovici-Muller J,
    4. Palaskas N, et al

    . An inhibitor of-mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626–30 doi:10.1126/science.1236062 pmid:23558169

    Abstract/FREE Full Text
17. 17.↵
    2. Zhou H,
    3. Vallières M,
    4. Bai HX, et al

    . MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 2017;19:862–870 doi:10.1093/neuonc/now256 pmid:28339588

    CrossRefPubMed
18. 18.↵
    2. Zhang CB,
    3. Bao ZS,
    4. Wang HJ, et al

    . Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. J Cancer Res Clin Oncol 2014;140:45–51 doi:10.1007/s00432-013-1519-9 pmid:24149775

    CrossRefPubMed
19. 19.↵
    2. Sonoda Y,
    3. Shibahara I,
    4. Kawaguchi T, et al

    . Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 2015;32:99–104 doi:10.1007/s10014-014-0211-3 pmid:25537428

    CrossRefPubMed
20. 20.↵
    2. Reyes-Botero G,
    3. Dehais C,
    4. Idbaih A, et al

    . Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 2014;16:662–70 doi:10.1093/neuonc/not235 pmid:24353325

    CrossRefPubMed
21. 21.↵
    2. Lai A,
    3. Kharbanda S,
    4. Pope WB, et al

    . Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482–90 doi:10.1200/JCO.2010.33.8715 pmid:22025148

    Abstract/FREE Full Text
22. 22.↵
    2. Persson AI,
    3. Petritsch C,
    4. Swartling FJ, et al

    . Non-stem cell origin for oligodendroglioma. Cancer Cell 2010;18:669–82 doi:10.1016/j.ccr.2010.10.033 pmid:21156288

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Metellus P,
    3. Coulibaly B,
    4. Colin C, et al

    . Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719–29 doi:10.1007/s00401-010-0777-8 pmid:21080178

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Qi S,
    3. Yu L,
    4. Li H, et al

    . Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 2014;7:1895–902 doi:10.3892/ol.2014.2013 pmid:24932255

    CrossRefPubMed
25. 25.↵
    2. Colen RR,
    3. Vangel M,
    4. Wang J, et al

    . Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. BMC Med Genomics 2014;7:30 doi:10.1186/1755-8794-7-30 pmid:24889866

    CrossRefPubMed
26. 26.↵
    2. Gevaert O,
    3. Mitchell LA,
    4. Achrol AS, et al

    . Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 2014;273:168–74 doi:10.1148/radiol.14131731 pmid:24827998

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Price SJ,
    3. Allinson K,
    4. Liu H, et al

    . Less invasive phenotype found in isocitrate dehydrogenase–mutated glioblastomas than in isocitrate dehydrogenase wild-type glioblastomas: a diffusion-tensor imaging study. Radiology 2017;283:215–21 doi:10.1148/radiol.2016152679 pmid:27849434

    CrossRefPubMed
28. 28.↵
    2. Xiong J,
    3. Tan W,
    4. Wen J, et al

    . Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol 2016;26:1705–15 doi:10.1007/s00330-015-4025-4 pmid:26396108

    CrossRefPubMed
29. 29.↵
    2. Xing Z,
    3. Yang X,
    4. She D, et al

    . Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol 2017;38:1138–44 doi:10.3174/ajnr.A5171 pmid:28450436

    Abstract/FREE Full Text
30. 30.↵
    2. Tan W,
    3. Huang W,
    4. Yin B, et al

    . Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. AJNR Am J Neuroradiol 2014;35:920–27 doi:10.3174/ajnr.A3803 pmid:24557705

    Abstract/FREE Full Text
31. 31.↵
    2. Beppu T,
    3. Inoue T,
    4. Shibata Y, et al

    . Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol 2005;63:56–61; discussion 61 doi:10.1016/j.surneu.2004.02.034 pmid:15639528

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Sanson M,
    3. Marie Y,
    4. Paris S, et al

    . Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–54 doi:10.1200/JCO.2009.21.9832 pmid:19636000

    Abstract/FREE Full Text
33. 33.↵
    2. Colen RR,
    3. Vangel M,
    4. Wang J, et al

    ; TCGA Glioma Phenotype Research Group. Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. BMC Med Genomics 2014;7:30 doi:10.1186/1755-8794-7-30 pmid:24889866

    CrossRefPubMed
34. 34.↵
    2. Lim DA,
    3. Cha S,
    4. Mayo MC, et al

    . Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 2007;9:424–29 doi:10.1215/15228517-2007-023 pmid:17622647

    CrossRefPubMed
35. 35.↵
    2. van den Bent MJ

    . Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 2014;16:1570–74 doi:10.1093/neuonc/nou297 pmid:25355680

    CrossRefPubMed
36. 36.↵
    2. Suzuki H,
    3. Aoki K,
    4. Chiba K, et al

    . Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015;47:458–68 doi:10.1038/ng.3273 pmid:25848751

    CrossRefPubMed
37. 37.↵
    2. Aldape K,
    3. Burger PC,
    4. Perry A

    . Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007;131:242–51 pmid:17284109

    PubMedWeb of Science
38. 38.↵
    2. Khayal IS,
    3. Vandenberg SR,
    4. Smith KJ, et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol 2011;13:1192–201 doi:10.1093/neuonc/nor122 pmid:21865401

    CrossRefPubMed
39. 39.↵
    2. Jenkinson MD,
    3. du Plessis DG,
    4. Smith TS, et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91 doi:10.1093/brain/awl108 pmid:16670176

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Fellah S,
    3. Caudal D,
    4. De Paula AM, et al

    . Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 2013;34:1326–33 doi:10.3174/ajnr.A3352 pmid:23221948

    Abstract/FREE Full Text
41. 41.↵
    2. Jenkinson MD,
    3. du Plessis DG,
    4. Smith TS, et al

    . Cellularity and apparent diffusion coefficient in oligodendroglial tumours characterized by genotype. J Neurooncol 2010;96:385–92 doi:10.1007/s11060-009-9970-9 pmid:19618117

    CrossRefPubMed